Friday, 20 November 2026
M
Meridian Globe
Live briefing
[Editorial] Multiple sclerosis: beyond controlling relapses— 柳叶刀 Lancet[Comment] Remibrutinib: a high-efficacy disease-modifying drug for relapsing multiple sclerosis?— 柳叶刀 Lancet[Comment] Expanding the post-EGFR TKI landscape with antibody–drug conjugates— 柳叶刀 Lancet[Comment] Sacituzumab tirumotecan in previously treated endometrial cancer— 柳叶刀 Lancet[Comment] Retraction: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother— 柳叶刀 Lancet[Comment] Offline: A manifesto for protecting public health— 柳叶刀 Lancet[World Report] Türkiye's coal industry draws criticism— 柳叶刀 Lancet[World Report] Research Focus: Te Poutoko Ora a Kiwa (Centre for Pacific and Global Health)— 柳叶刀 Lancet[Editorial] Multiple sclerosis: beyond controlling relapses— 柳叶刀 Lancet[Comment] Remibrutinib: a high-efficacy disease-modifying drug for relapsing multiple sclerosis?— 柳叶刀 Lancet[Comment] Expanding the post-EGFR TKI landscape with antibody–drug conjugates— 柳叶刀 Lancet[Comment] Sacituzumab tirumotecan in previously treated endometrial cancer— 柳叶刀 Lancet[Comment] Retraction: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother— 柳叶刀 Lancet[Comment] Offline: A manifesto for protecting public health— 柳叶刀 Lancet[World Report] Türkiye's coal industry draws criticism— 柳叶刀 Lancet[World Report] Research Focus: Te Poutoko Ora a Kiwa (Centre for Pacific and Global Health)— 柳叶刀 Lancet

India 16 without loss in reply to New Zealand's 368 in first test

Source CNA亚洲新闻台12h ago
Summary

We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.

Open original
Desk
World
Region
Singapore
Language
English
Item ID
world-93939e3b

Comments 0 comments

No comments yet. Be the first.

India 16 without loss in reply to New Zealand's 368 in first test · Meridian Globe